Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTR087 + Rituximab in Relapsed/Refractory CD20+ B-Cell Lymphoma
NCT02776813Phase 1Completed
- Sponsor
- Cogent Biosciences
- Start
- Aug 2016
- Primary completion
- Feb 2020
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACTR087 in B cell lymphoma, sponsored by Cogent Biosciences. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 24 months and 3 more. Started Aug 2016; status: completed.
02
Drugs
ACTR087
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02776813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776813.